Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab
Gains Rights To Perjeta And Prolia/Xgeva Biosimilars As Well As Ipilimumab Option
• By David Wallace
US-based Organon has struck a deal with China’s Henlius • Source: Shutterstock 
